Innovative CD99 Inhibitors for Cancer and Autoimmune Disease Treatment

OVERVIEW

This invention presents novel small molecule inhibitors of CD99, offering a new therapeutic approach for treating bone and connective tissue cancers, particularly those expressing CD99 antigens. The CD99 inhibitors, including clofarabine, cladribine, and their 5' triphosphate analogs, are designed to target CD99+ cancers effectively. The treatment involves administering these inhibitors in effective amounts to patients, providing a potentially superior alternative to existing cancer therapies by focusing on the CD99 antigen, thus enhancing the specificity and efficacy of the treatment.

BACKGROUND

Cancer remains a leading cause of death globally, with over 1.6 million new cases diagnosed annually in the US alone. There is a significant demand for more effective and targeted cancer treatments. Additionally, autoimmune diseases affect over 50 million Americans, highlighting the need for novel therapeutic strategies. The development of CD99 inhibitors addresses these critical healthcare challenges by offering targeted treatment options for CD99+ cancers and autoimmune disorders.

Benefit

• Targeted Therapy: Specifically targets CD99+ cancer cells, minimizing damage to healthy tissues.
• Dual Application: Effective for both cancer and autoimmune diseases, broadening its therapeutic utility.
• High Specificity: Membrane impermeable inhibitors ensure higher specificity and reduced side effects.
• Innovative Treatment: Introduces a novel mechanism of action, potentially overcoming resistance seen in traditional therapies.
• Enhanced Efficacy: Potentially more effective in treating hard-to-treat cancers like bone and connective tissue cancers.

Market Application

• Oncology: Treatment of CD99+ bone and connective tissue cancers.
• Autoimmune Disorders: Management of autoimmune diseases with targeted CD99 inhibition.
• Pharmaceutical Development: Basis for new cancer and autoimmune disease drugs.
• Precision Medicine: Incorporation into personalized treatment plans for cancer patients.
• Clinical Research: Foundation for further studies in targeted cancer therapies and immune modulation.

Publications

US Issued patent No. 11,202,792